This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by BAR-SHAVIT, Z. Articles by TEITELBAUM, S. L. Search for Related Content PubMed PubMed Citation Articles by BAR-SHAVIT, Z. Articles by TEITELBAUM, S. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 1,25-DIHYDROXYCHOLECALCIFEROL

Reversibility of Vitamin D-Induced Human Leukemia Cell-Line Maturation^*

ZVI BAR-SHAVIT, ARNOLD J. KAHN, KENNETH R. STONE, JOANN TRIAL, TOM HILLIARD, PIETER H. REITSMA and STEVEN L. TEITELBAUM

Division of Cell Biology, Washington University School of Medicine St. Louis, Missouri 63110
Washington University School of Dental Medicine, Department of Pathology, Washington University School of Medicine St. Louis, Missouri 63110
The Jewish Hospital at Washington University Medical Center, and Department of Genetics, Washington University School of Medicine St. Louis, Missouri 63110

Address requests for reprints to: Zvi Bar-Shavit, Ph.D., Department of Pathology, The Jewish Hospital at Washington University Medical Center, 216 South Kingshighway, St. Louis, Missouri 63110.

Abstract

HL-60 cells are induced to differentiate along a monocytic pathway by the active metabolites of vitamin D₃, e.g. 1,25-dihydroxyvitamin D₃ [1,25-(OH)₂D₃]. All such differentiated cells share a number of features in common but are heterogeneous in their ability to adhere to solid substrates and to resorb devitalized bone matrix. Here, we show that, in addition, as compared to the nonadherent, adherent cells are smaller, less likely to be in the S phase, more enriched in the human monocyte-specific cell surface antigen, 63D3, and contain less cmyc messenger RNA (mRNA). In addition, we document that removal of the hormone leads to dedifferentiation. For these susceptible mononuclear cells, removal of 1,25-(OH)₂D₃ results in a reversion to a more myeloblastic phenotype, renewed cell proliferation, and the rapid appearance of elevated levels of cmyc mRNA. Finally, we report that the cells that do not revert upon 1,25-(OH)₂D₃ removal are those that became multinucleated during treatment. (Endocrinology 118: 679–686, 1986)

Footnotes

^* This work was supported by PHS Grants AM-34401 (to Z.B.), DE-05413 (to S.L.T.), DE-04629 (to A.J.K.), a NIH BRSG grant award to Washington University School of Dental Medicine (to Z.B.), and Grant IN36 from the American Cancer Society (to P.H.R.).

Recipient of an Arthritis Foundation Investigator Award.

Received April 9, 1985.